Prophylactic deoxyspergualin treatment in living-related renal-transplant recipients transfused with donor-specific blood

Transplantation

Volumn 75, Issue 1, 2003, Pages 60-66

  Amada, Noritoshi ^a   Okazaki, Hajime ^a   Sato, Takaomi ^a   Miura, Shunji ^a   Ohashi, Yoichi ^a  

^a Sendai Shakaihoken Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; OKT 3;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHILD; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GUANIDINES; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED;

EID: 0037439802     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200301150-00011     Document Type: Article

References (23)

1. Shoskes DA. Immunologic tolerance in renal transplantation. World J Urol 1996; 14: 218.
2. Salvatierra O Jr, Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg 1980; 192: 543.
3. Potter DE, Portale AA, Melzer JS, et al. Are blood transfusions beneficial in the cyclosporine era? Pediatr Nephrol 1991; 5: 168.
4. Alexander JW, Light JA, Donaldson LA, et al. Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Transplantation 1999; 68: 1117.
5. Flye MW, Burton K, Mohanakumar T, et al. Donor-specific transfusions have long-term beneficial effects for human renal allografts. Transplantation 1995; 60: 1395.
6. Sanfilippo F, Thacker L, Vaughn WK. Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome. Transplantation 1990; 49: 25.
7. Okazaki H, Sato T, Miura S, et al. Donor-specific blood transfusion in living-related renal transplantation: fourteen-year experience. Transplant Proc 1997; 29: 200.
8. Humar A, Payne WD, Sutherland DE, et al. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69: 2357.
9. Humar A, Kerr S, Gillingham KJ, et al. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200.
10. Ishikawa A, Flechner SM, Goldfarb DA, et al. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 1999; 68: 1318.
11. Vereerstraeten P, Abramowicz D, Pauw L, et al. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739.
12. Okazaki H, Sato T, Amada N. Further study of deoxyspergualin prophylaxis in living related renal transplantation. Transplant Proc 1993; 25: 772.
13. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant Proc 1990; 22: 1357.
14. Nishimura N, Tokunaga T. Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. Immunology 1989; 68: 66.
15. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 1992; 54: 526.
16. Nemoto K, Abe F, Nakamura T, et al. Blastogenic responses and the release of interleukin 1 and 2 by spleen cells obtained from rat skin allograft recipients administered with 15-deoxyspergualin. J Antibiot (Tokyo) 1987; 40: 1062.
17. Tanabe K, Takahashi K, Nemoto K, et al. Effect of deoxyspergualin on vascular rejection in canine kidney transplantation. J Urol 1994; 152: 562.
18. Tanabe K, Yasuo M, Nemoto K, et al. Synergistic effect of donor-specific blood transfusion and a short course of deoxyspergualin in rat kidney transplantation. Transpl Int 1996; 9: 353.
19. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
20. Rush DN, Karpinski ME, Nickerson P, et al. Does subclinical rejection contribute to chronic rejection in renal transplant patients? Clin Transplant 1999; 13: 441.
21. Cecka JM. The UNOS Scientific Renal Transplant Registry. In: JM Cecka, PI Terasaki, eds. Clinical transplants 2000. UCLA Immunogenetics Center, Los Angeles 2001, 1.
22. Amada N, Okazaki H, Sato T, et al. Beneficial effects of 15-deoxyspergualin on late acute rejection occurring more than three months after renal transplantation. Transplant Proc 1998; 30: 2246.
23. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65: 224.